{
    "clinical_study": {
        "@rank": "48603", 
        "arm_group": [
            {
                "arm_group_label": "Miscarriage", 
                "description": "Women with fetal death prior to 20 weeks gestation."
            }, 
            {
                "arm_group_label": "Intrauterine Fetal Demise", 
                "description": "Women presenting with stillbirth, defined as fetal death occurring after 20 weeks gestation."
            }
        ], 
        "biospec_descr": {
            "textblock": "Blood collection will consist of two ten milliliters samples of whole blood in the cffDNA\n      STRECK tube.  Plasma will be retained for analysis of circulating cell free fetal DNA."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Women presenting to Washington Hospital Center with fetal loss would be offered\n      participation in the study.  The objective is to determine if ccffDNA obtained from maternal\n      blood is present in the setting of missed abortion or fetal demise.\n\n      The investigators primary hypothesis is that cell free fetal DNA will be present in maternal\n      blood in the presence of a failed pregnancy."
        }, 
        "brief_title": "The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Circulating Cell Free Fetal DNA", 
            "Intrauterine Fetal Demise", 
            "Miscarriage"
        ], 
        "condition_browse": {
            "mesh_term": "Abortion, Spontaneous"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Women diagnosed with Intrauterine fetal demised or missed abortion\n\n        Exclusion Criteria:\n\n          -  Patients diagnosed with threatened abortion with cardiac activity present\n\n          -  Patients with IUFD who have delivered the fetus (the induction process may already be\n             in process, however, the fetus and placenta must be in situ at the time of blood\n             sampling)\n\n          -  Patients with known genetic abnormalities or mental retardation as a result of\n             chromosomal abnormalities 13, 18, 21, or sex chromosomes.\n\n          -  Children under the age of 18\n\n          -  Patients not fluent in or unable to consent to the study in English"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Women presenting to Washington Hospital Center with fetal loss would be offered DNA\n        sequencing of cell free fetal DNA from maternal blood in addition to the standard workup\n        for fetal demise and miscarriage as deemed appropriate by the patient's care provider.\n        Only women with sonographic evidence of products of conception in-utero will be offered\n        enrollment."
            }
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01916928", 
            "org_study_id": "MedStarWHC-OB"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Circulating cell free fetal DNA", 
            "Intrauterine fetal demise", 
            "Miscarriage"
        ], 
        "lastchanged_date": "August 5, 2013", 
        "location": {
            "contact": {
                "email": "cecily.a.clark-ganheart@medstar.net", 
                "last_name": "Cecily A Clark-Ganheart, MD", 
                "phone": "202-801-2186"
            }, 
            "facility": {
                "address": {
                    "city": "Washington", 
                    "country": "United States", 
                    "state": "District of Columbia", 
                    "zip": "20010"
                }, 
                "name": "Medstar Washington Hospital Center"
            }, 
            "investigator": [
                {
                    "last_name": "Rita W Driggers, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Cecily A Clark-Ganheart, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "The Use of Cell Free Fetal DNA in the Maternal Blood in the Evaluation of Intrauterine Fetal Demise and Miscarriage", 
        "overall_contact": {
            "email": "Rita.W.Driggers@medstar.net", 
            "last_name": "Rita W. Driggers, MD", 
            "phone": "202-877-7127"
        }, 
        "overall_contact_backup": {
            "email": "ganheartmd@gmail.com", 
            "last_name": "Cecily A Clark-Ganheart, MD", 
            "phone": "2692092048"
        }, 
        "overall_official": {
            "affiliation": "Medstar Washington Hospital Center", 
            "last_name": "Rita W Driggers, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The presence or absence of cell free fetal DNA in maternal blood in the setting of a failed pregnancy.", 
            "safety_issue": "No", 
            "time_frame": "During initial presentation for treatment"
        }, 
        "reference": [
            {
                "PMID": "15210050", 
                "citation": "Nagaishi M, Yamamoto T, Iinuma K, Shimomura K, Berend SA, Knops J. Chromosome abnormalities identified in 347 spontaneous abortions collected in Japan. J Obstet Gynaecol Res. 2004 Jun;30(3):237-41."
            }, 
            {
                "PMID": "11522246", 
                "citation": "Baena N, Guitart M, Ferreres JC, Gabau E, Corona M, Mellado F, Egozcue J, Caball\u00edn MR. Fetal and placenta chromosome constitution in 237 pregnancy losses. Ann Genet. 2001 Apr-Jun;44(2):83-8."
            }, 
            {
                "PMID": "8885928", 
                "citation": "Kyle PM, Sepulveda W, Blunt S, Davies G, Cox PM, Fisk NM. High failure rate of postmortem karyotyping after termination for fetal abnormality. Obstet Gynecol. 1996 Nov;88(5):859-62."
            }, 
            {
                "PMID": "19294965", 
                "citation": "MacDorman MF, Kirmeyer S. Fetal and perinatal mortality, United States, 2005. Natl Vital Stat Rep. 2009 Jan 28;57(8):1-19."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01916928"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Medstar Research Institute", 
            "investigator_full_name": "Cecily A. Clark-Ganheart MD", 
            "investigator_title": "Director of Maternal Fetal Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "measure": "The accuracy of ccffDNA compared to genetic information obtained from amniocentesis, chorionic villus sampling, fetal, or placental tissue.", 
            "safety_issue": "No", 
            "time_frame": "3-4 weeks after specimen processing"
        }, 
        "source": "Medstar Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Medstar Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}